- 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
- 4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
- 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
- 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
- 4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
- 4DMT to Participate in Upcoming Investor Conferences
- 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
- 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
- 4DMT to Participate in Upcoming Investor Conference
- 4DMT Announces Presentations at ARVO 2024 Annual Meeting
More ▼
Key statistics
As of last trade, 4D Molecular Therapeutics Inc (FDMT:NSQ) traded at 21.15, 124.05% above the 52 week low of 9.44 set on Oct 17, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.68 |
---|---|
High | 21.20 |
Low | 20.56 |
Bid | 20.50 |
Offer | 25.00 |
Previous close | 20.85 |
Average volume | 783.67k |
---|---|
Shares outstanding | 51.70m |
Free float | 49.35m |
P/E (TTM) | -- |
Market cap | 1.09bn USD |
EPS (TTM) | -2.36 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼